Effect of HM910, a Novel Camptothecin Derivative, on the Inhibition of Multiple Myeloma Cell Growth in Vitro and in Vivo

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2015 Jun 6

PMID 26045982

Citations 5

Authors

Juan Li

Yudan Ouyang

Xu Zhang

Wenqiang Zhou

Fang Wang

Zhencong Huang

Xiaokun Wang

Yifan Chen

Hui Zhang

Liwu Fu

Affiliations

Soon will be listed here.

Abstract

Despite a variety of novel therapeutic agents, such as bortezomib, thalidomide and topotecan, multiple myeloma (MM) remains an incurable disease, thus the development of new chemotherapeutical agents is of high priority. We found HM910, a novel camptothecin (CPT) derivative, exhibited potent inhibition of MM cell growth in vitro and in xenografts of nude mice. Mechanistically, HM910 reduced the mitochondrial transmembrane potential (ΔΨm) via an increase in reactive oxygen species (ROS), which eventually resulting in the release of cytochrome c and the activation of mitochondrial-dependent apoptotic pathway. On the other hand, HM910 significantly triggered cell cycle arrest in G1 phase via downregulating the expressions of cyclin dependent kinase (CDK) 4 and 6, resulting in down-regulation of cyclin D1. Therefore, HM910 maybe a promising candidate for treating MM patients and is currently in phase I clinical trial in China.

Citing Articles

Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?.

Li F, Jiang T, Li Q, Ling X Am J Cancer Res. 2018; 7(12):2350-2394.

PMID: 29312794 PMC: 5752681.

Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.

Xie F, Pan S, Ou R, Zheng Z, Huang X, Jian M Am J Cancer Res. 2016; 5(12):3548-59.

PMID: 26885445 PMC: 4731630.

Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis.

Wang Z, Wei S, Wang Q Am J Cancer Res. 2016; 5(11):3339-49.

PMID: 26807315 PMC: 4697681.

Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.

Mei X, Yang Y, Zhang Y, Li Y, Zhao J, Qiu J Am J Cancer Res. 2016; 5(11):3311-24.

PMID: 26807313 PMC: 4697679.

Macrophage Migration Inhibitory Factor Secretion Is Induced by Ionizing Radiation and Oxidative Stress in Cancer Cells.

Gupta Y, Pasupuleti V, Du W, Welford S PLoS One. 2016; 11(1):e0146482.

PMID: 26741693 PMC: 4704778. DOI: 10.1371/journal.pone.0146482.

References

Quinn J, Glassford J, Percy L, Munson P, Marafioti T, Rodriguez-Justo M . APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood. 2010; 117(3):890-901. DOI: 10.1182/blood-2010-01-264424. View

Podar K, Tai Y, Hideshima T, Vallet S, Richardson P, Anderson K . Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009; 14(1):99-127. PMC: 3183751. DOI: 10.1517/14728210802676278. View

Pommier Y, Marchand C . Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov. 2011; 11(1):25-36. PMC: 7380715. DOI: 10.1038/nrd3404. View

Landgren O, Kyle R, Pfeiffer R, Katzmann J, Caporaso N, Hayes R . Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113(22):5412-7. PMC: 2689042. DOI: 10.1182/blood-2008-12-194241. View

Glassford J, Kassen D, Quinn J, Stengel C, Kallinikou K, Khwaja A . Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations. Blood Cancer J. 2012; 2(1):e50. PMC: 3270251. DOI: 10.1038/bcj.2011.44. View

Malumbres M, Barbacid M . Cell cycle kinases in cancer. Curr Opin Genet Dev. 2007; 17(1):60-5. DOI: 10.1016/j.gde.2006.12.008. View

Marchal J, Carrasco E, Ramirez A, Jimenez G, Olmedo C, Peran M . Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence. Drug Des Devel Ther. 2013; 7:1301-13. PMC: 3815003. DOI: 10.2147/DDDT.S51354. View

Kazmi S, Saliba R, Donato M, Wang M, Hosing C, Qureshi S . Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2010; 46(4):510-5. PMC: 4080410. DOI: 10.1038/bmt.2010.160. View

LeBlanc R, Catley L, Hideshima T, Lentzsch S, Mitsiades C, Mitsiades N . Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002; 62(17):4996-5000. View

10.

Tsujimoto Y . Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol. 2003; 195(2):158-67. DOI: 10.1002/jcp.10254. View

11.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

12.

Rogalska A, Koceva-Chyla A, Jozwiak Z . Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines. Chem Biol Interact. 2008; 176(1):58-70. DOI: 10.1016/j.cbi.2008.07.002. View

13.

Kyle R, Rajkumar S . Multiple myeloma. N Engl J Med. 2004; 351(18):1860-73. DOI: 10.1056/NEJMra041875. View

14.

Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J . Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012; 120(5):1095-106. PMC: 3412331. DOI: 10.1182/blood-2012-03-415984. View

15.

van de Donk N, Lokhorst H . New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother. 2013; 14(12):1569-73. DOI: 10.1517/14656566.2013.805746. View

16.

Ou Y, Dong X, Liu X, Cheng X, Cheng Y, Yu L . Mechanism of tetramethylpyrazine analogue CXC195 inhibition of hydrogen peroxide-induced apoptosis in human endothelial cells. Biol Pharm Bull. 2010; 33(3):432-8. DOI: 10.1248/bpb.33.432. View

17.

Yan Y, Su X, Liang Y, Zhang J, Shi C, Lu Y . Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage. Mol Cancer Ther. 2008; 7(6):1688-97. DOI: 10.1158/1535-7163.MCT-07-2362. View

18.

Lamb R, Lehn S, Rogerson L, Clarke R, Landberg G . Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle. 2013; 12(15):2384-94. PMC: 3841318. DOI: 10.4161/cc.25403. View

19.

Liu S, Bolger J, Kirkland L, Premnath P, McInnes C . Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol. 2010; 5(12):1169-82. PMC: 3425359. DOI: 10.1021/cb1001262. View

20.

Wan Q, Wang H, Lin Y, Gu L, Han M, Yang Z . Effects of quercetin on CDK4 mRNA and protein expression in A549 cells infected by H1N1. Biomed Rep. 2014; 1(5):766-770. PMC: 3917044. DOI: 10.3892/br.2013.141. View